Fuchs' Dystrophy clinical trials at UCLA
2 in progress, 0 open to eligible people
K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
Sorry, in progress, not accepting new patients
A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.
Los Angeles, California and other locations
STN1010904 Ophthalmic Suspension 0.03% and 0.1% Compared With Vehicle in Subjects With Fuchs Endothelial Corneal Dystrophy (FECD)
Sorry, in progress, not accepting new patients
This is a Phase IIa study to assess efficacy and safety of STN1010904 ophthalmic suspension (0.03%, and 0.1 %), twice daily dosing when compared to Placebo in subjects diagnosed with Fuchs Endothelial Corneal Dystrophy (FECD). This study will consist of a Screening Period of up to 15 days and an 18-month Double-Masked Treatment Period, including 9 individual visits to the study site.
Los Angeles, California and other locations
Our lead scientists for Fuchs' Dystrophy research studies include Sophie X. Deng, MD, PhD.
Last updated: